Hutch News

Stories tagged 'Philip D Greenberg'

A Q&A with Fred Hutch postdoctoral research fellow Dr. Rachel Perret

As part of a world-class immunotherapy research team, Perret is working her ‘dream job’ — trying to bring T-cell therapy to all who need it

Jan. 9, 2017 | By Rachel Tompa / Fred Hutch News Service

A postdoctoral research fellow training under the mentorship of immunotherapy expert Dr. Phil Greenberg, Dr. Rachel Perret is working toward an “off-the-shelf” version of T-cell therapy.

View story >


‘A place where miracles happen’: Opening of Bezos Family Immunotherapy Clinic highlights patient-focused science

Research symposium and ribbon cutting celebrates first-of-its-kind facility for experimental immunotherapies

Dec. 16, 2016 | By Susan Keown / Fred Hutch News Service

Lymphoma survivor Stephanie Florence said she wouldn't be alive if not for the science done at Fred Hutchinson Cancer Research Center. This week, she cut the ribbon at the grand opening of the Bezos Family Immunotherapy Clinic, which will make it possible for twice as many patients like Florence to receive treatment.

View story >


Immunotherapy shows promise in preventing leukemia relapse

Group of 12 high-risk patients who received engineered T cells after bone marrow transplant still in remission after more than two years

Dec. 5, 2016 | By Susan Keown / Fred Hutch News Service

For patients with high-risk acute myeloid leukemia, relapse after bone marrow transplant signals a low chance of survival. But results from a small trial of genetically engineered immune cells show promise for keeping these patients out of danger: Of the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.

View story >


Promising results in trial of engineered T cells in high-risk leukemia

High response rates to experimental immunotherapy in patients with treatment-resistant chronic lymphocytic leukemia

Dec. 3, 2016 | By Susan Keown / Fred Hutch News Service

Most patients with recurrent chronic lymphocytic leukemia who were enrolled in a small, early- phase trial saw their advanced tumors shrink or even disappear after an infusion of genetically engineered immune cells. Dr. Cameron Turtle, one of the study’s leaders, presented the results on Saturday at the 2016 annual meeting of the American Society of Hematology in San Diego.

View story >


‘I ride for...’ : 4th annual Obliteride raises nearly $2M — and counting — for Fred Hutch

More than 1,500 cyclists pedaled across the finish line this weekend — with names of survivors, patients and loved ones lost to cancer surrounding them

Aug. 15, 2016 | By Rachel Tompa / Fred Hutch News Service

This weekend’s fourth annual Obliteride fundraising bike ride for Fred Hutch involved more than 1,500 riders who have so far raised nearly $2 million for Fred Hutch’s cancer research, with donations continuing to roll in for the next month.

View story >


Good News at Fred Hutch

Celebrating faculty and staff achievements

Aug. 11, 2016

Dr. Amit Sharma receives Pathway to Independence Award; Dr. Phil Greenberg publishes T-cell findings; Dr. Yanghee Woo chosen for early-career hematology training program

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.